文献速递衰弱、肌少症与跌倒老年慢病共病管理

欧洲房颤患者衰弱流行病学及影响

Epidemiology and impact of frailty in patients with atrial fibrillation in Europe.
PubMed 文献 · Age Ageing · 2022-01-01

基于ESC-EHRA EORP-AF长期注册研究,对10,177例欧洲房颤患者采用40项衰弱指数评估,发现59.6%为前衰弱、21.3%为衰弱,仅19.1%健壮。衰弱与血栓栓塞及出血风险独立相关,降低口服抗凝药使用率,且与所有不良结局呈非线性指数关系;口服抗凝药获益在高衰弱患者中维持,但在极高/极度衰弱者中未维持。

要点

  • 欧洲房颤患者中衰弱负担高:21.3%衰弱,59.6%前衰弱。
  • 衰弱患者口服抗凝药使用率更低(OR 0.70,95%CI 0.55-0.89)。
  • 口服抗凝药获益在高衰弱患者中维持,极高/极度衰弱者未维持。

核心结论

  • 房颤患者中衰弱负担高,衰弱影响临床管理与不良结局风险。
  • 口服抗凝药的临床获益在高衰弱患者中维持,但在极高/极度衰弱患者中未维持。

研究设计与样本

  • 基于ESC-EHRA EORP-AF长期注册研究,采用40项衰弱指数(FI)按缺陷累积模型评估房颤患者。
  • 共纳入10,177例患者,平均年龄69.0岁(标准差11.4),女性4,103例(40.3%)。

主要发现

  • 6,066例(59.6%)为前衰弱,2,172例(21.3%)为衰弱,仅1,939例(19.1%)为健壮。
  • 基线血栓栓塞及出血风险与FI增加独立相关。
  • 衰弱房颤患者接受口服抗凝药(OAC)治疗的可能性更低(OR 0.70,95%CI 0.55-0.89),尤其是非维生素K拮抗剂OAC及节律控制策略。
  • 衰弱程度增加与所有考察结局风险升高相关,呈非线性指数关系。
  • 使用OAC与较低结局风险相关,但在极高/极度衰弱患者中例外。

临床怎么用

  • 对房颤患者应评估衰弱状态,衰弱影响抗凝及节律控制策略的选择。
  • 高衰弱房颤患者仍可从OAC治疗中获益,但极高/极度衰弱者需个体化权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES: We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS: A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS: Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS: In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Proietti M, Romiti GF, Vitolo M, et al. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing. 2022. PMID: 35997262. doi:10.1093/ageing/afac192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。